Alivus Life Sciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Million)
Alivus Life Sciences Ltd · Financial Result · 30 Oct 2026, 12:51 am
Alivus Life Sciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Million) ■ Revenue: 6,820 (+16.0% YoY | +6.5% QoQ) ■ EBITDA: 2,652 (+48.0% YoY | +25.3% QoQ) ■ EBITDA Margin (%): 38.9 (+841 bps YoY | +583 bps QoQ) ■ PAT: 1,967 (+51.3% YoY | +22.9% QoQ) ■ EPS (INR): 16.0 (+51.0% YoY | +22.8% QoQ)
Original exchange filing (PDF)
More announcements from Alivus Life Sciences Ltd
- Enclosed please find herewith update on acquisition. · 11 Nov 2026
- Please find enclosed herewith disclosure under Regulation 30 of SEBI(LODR), 2015. · 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd · 07 Nov 2026
- Please find attached herewith submission with respect to transcript of the earning call. · 06 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor meeting. · 04 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor Meet. · 30 Oct 2026
- We hereby confirm that we have uploaded audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026 on the website of the Company. · 30 Oct 2026
- Please find enclosed herewith intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021" · 30 Oct 2026
